The historical rank and industry rank for Belluscura's EV-to-EBIT or its related term are showing as below:
LSE:BELL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -121.12 Med: -13.8 Max: -1.32
Current: -1.51
During the past 5 years, the highest EV-to-EBIT of Belluscura was -1.32. The lowest was -121.12. And the median was -13.80.
LSE:BELL's EV-to-EBIT is ranked worse than 100% of 458
companies
in the Medical Devices & Instruments industry
Industry Median: 20.495
vs LSE:BELL: -1.51
The historical data trend for Belluscura's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Belluscura's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belluscura's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Belluscura's EV-to-EBIT falls into.
Belluscura EV-to-EBIT Calculation
Belluscura's EV-to-EBIT for today is calculated as:
Belluscura's current Enterprise Value is £11.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Belluscura's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-7.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura (LSE:BELL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Belluscura's Enterprise Value for the quarter that ended in Jun. 2023 was £41.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Belluscura's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-7.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Belluscura's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:BELL has been successfully added to your 